Ricciardi Rocco, Madoff Robert D, Rothenberger David A, Baxter Nancy N
Department of Surgery, University of Minnesota Medical School, Minneapolis, Minnesota, USA, and St. Michael's Hospital, University of Toronto, Ontario, Canada.
Clin Gastroenterol Hepatol. 2006 Dec;4(12):1522-7. doi: 10.1016/j.cgh.2006.07.016. Epub 2006 Sep 18.
BACKGROUND & AIMS: The potential presence of lymph node metastases in patients with colorectal cancer (CRC) limits the application of minimally invasive techniques of resection. We used data from the National Cancer Institute's Surveillance, Epidemiology, and End Results registry to better understand the underlying risk of lymph node metastases and factors that influence this risk in a population-based fashion.
In a cohort of 124,180 CRC patients diagnosed from 1988 through 2002 treated with radical surgery without neoadjuvant irradiation, we assessed the proportion of patients who were lymph node positive and determined factors that influenced the risk of lymph node metastases including patient characteristics, anatomic location, and histopathologic factors.
Among all patients, the proportion of lymph node metastases was 34.5%. The overall proportion of node positivity was 8% for T1 tumors, 18.5% for T2 tumors, 42% for T3 tumors, and 50% for T4 tumors. Nodal metastases were noted in 7% of proximal T1 colon tumors, 7.5% of distal T1 colon tumors, and 10.1% of T1 rectal tumors. Patients with poorly differentiated tumors were much more likely to be node positive (52%) than patients with well-differentiated tumors (20%) (P<.0001).
Even patients with superficial CRCs have a significant risk of nodal metastases. This risk should be considered when balancing the risks and benefits of minimally invasive techniques such as local excision or endoscopic resection for the treatment of CRC.
结直肠癌(CRC)患者中潜在的淋巴结转移限制了微创切除技术的应用。我们利用美国国立癌症研究所监测、流行病学和最终结果登记处的数据,以基于人群的方式更好地了解淋巴结转移的潜在风险以及影响该风险的因素。
在一组1988年至2002年诊断的124180例接受根治性手术且未接受新辅助放疗的CRC患者中,我们评估了淋巴结阳性患者的比例,并确定了影响淋巴结转移风险的因素,包括患者特征、解剖位置和组织病理学因素。
在所有患者中,淋巴结转移的比例为34.5%。T1肿瘤的淋巴结阳性总体比例为8%,T2肿瘤为18.5%,T3肿瘤为42%,T4肿瘤为50%。在近端T1结肠癌患者中,7%存在淋巴结转移,远端T1结肠癌患者中为7.5%,T1直肠癌患者中为10.1%。低分化肿瘤患者的淋巴结阳性率(52%)远高于高分化肿瘤患者(20%)(P<0.0001)。
即使是浅表性CRC患者也有显著的淋巴结转移风险。在权衡局部切除或内镜切除等微创技术治疗CRC的风险和益处时,应考虑到这一风险。